Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn A Paxton

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in HIV and AIDS|October 4, 2012
Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settingsLynn A Paxton
Journal of Urban Health : Bulletin of the New York Academy of Medicine|June 1, 2006
Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United StatesScott S Santibanez, Richard S Garfein, Andrea Swartzendruber, et al.
AIDS and Behavior|September 5, 2014
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010Poloko M Kebaabetswe, Michael J Stirratt, Eleanor McLellan-Lemal, et al.
Plos One|March 15, 2014
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in BotswanaMichael Kasonde, Richard W Niska, Charles Rose, et al.
Plos One|April 10, 2014
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in BotswanaTebogo M Segolodi, Faith L Henderson, Charles E Rose, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 22, 2005
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human ServicesDawn K Smith, Lisa A Grohskopf, Roberta J Black, et al.
AIDS (London, England)|December 24, 2013
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxisLovemore I Chirwa, Jeffrey A Johnson, Richard W Niska, et al.
Plos One|March 27, 2014
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugsMichael Martin, Suphak Vanichseni, Pravan Suntharasamai, et al.
American Journal of Public Health|April 17, 2015
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012Suphak Vanichseni, Michael Martin, Pravan Suntharasamai, et al.
AIDS (London, England)|May 19, 2015
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugsMichael Martin, Suphak Vanichseni, Pravan Suntharasamai, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in HIV and AIDS|October 4, 2012
Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settingsLynn A Paxton
Journal of Urban Health : Bulletin of the New York Academy of Medicine|June 1, 2006
Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United StatesScott S Santibanez, Richard S Garfein, Andrea Swartzendruber, et al.
AIDS and Behavior|September 5, 2014
Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010Poloko M Kebaabetswe, Michael J Stirratt, Eleanor McLellan-Lemal, et al.
Plos One|March 15, 2014
Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in BotswanaMichael Kasonde, Richard W Niska, Charles Rose, et al.
Plos One|April 10, 2014
Normal laboratory reference intervals among healthy adults screened for a HIV pre-exposure prophylaxis clinical trial in BotswanaTebogo M Segolodi, Faith L Henderson, Charles E Rose, et al.
MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports|January 22, 2005
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human ServicesDawn K Smith, Lisa A Grohskopf, Roberta J Black, et al.
AIDS (London, England)|December 24, 2013
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxisLovemore I Chirwa, Jeffrey A Johnson, Richard W Niska, et al.
Plos One|March 27, 2014
Risk behaviors and risk factors for HIV infection among participants in the Bangkok tenofovir study, an HIV pre-exposure prophylaxis trial among people who inject drugsMichael Martin, Suphak Vanichseni, Pravan Suntharasamai, et al.
American Journal of Public Health|April 17, 2015
High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012Suphak Vanichseni, Michael Martin, Pravan Suntharasamai, et al.
AIDS (London, England)|May 19, 2015
The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugsMichael Martin, Suphak Vanichseni, Pravan Suntharasamai, et al.
Pageof 2